Email: cspc@cspc.cn
Media
News Center
Feb. 21
2024
First Human Study of CSPC's SYS6002 Presented at ASCO-GU
Feb. 07
VOLUNTARY ANNOUNCEMENT-INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (明復樂®) (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS M
Jan. 19
VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
CSPC Listed in Top 100 Enterprises in the Beijing-Tianjin-Hebei Region
CSPC Receives MSCI ESG A Rating for Three Consecutive Years
CSPC Attends 2023 Conference on the Development of China's Pharmaceutical Industry
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
